Analysts have been eager to weigh in on the Healthcare sector with new ratings on PROCEPT BioRobotics (PRCT – Research Report), American Well (AMWL – Research Report) and Glaukos (GKOS – Research Report).
PROCEPT BioRobotics (PRCT)
Wells Fargo analyst Nathan Treybeck assigned a Buy rating to PROCEPT BioRobotics yesterday and set a price target of $67.00. The company’s shares closed last Wednesday at $60.61, close to its 52-week high of $63.26.
According to TipRanks.com, Treybeck is a 4-star analyst with an average return of
PROCEPT BioRobotics has an analyst consensus of Strong Buy, with a price target consensus of $61.00, representing a 10.9% upside. In a report released yesterday, Leerink Partners also reiterated a Buy rating on the stock with a $64.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
American Well (AMWL)
In a report released today, Craig Hettenbach from Morgan Stanley maintained a Hold rating on American Well, with a price target of $1.00. The company’s shares closed last Wednesday at $0.53, close to its 52-week low of $0.50.
According to TipRanks.com, Hettenbach is ranked #770 out of 8802 analysts.
American Well has an analyst consensus of Hold, with a price target consensus of $1.76.
Glaukos (GKOS)
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Glaukos, with a price target of $110.00. The company’s shares closed last Wednesday at $98.91, close to its 52-week high of $103.66.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of
Glaukos has an analyst consensus of Strong Buy, with a price target consensus of $110.33, implying a 14.6% upside from current levels. In a report released today, Needham also reiterated a Buy rating on the stock with a $113.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PRCT:
- PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
- Procept BioRobotics announces 12 scientific research presentations
- PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting
- PROCEPT BioRobotics Announces Board Member Transition
- PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
